Efficacité de la prednisone (cortisone) pour le traitement de la myasthénie oculaire : Un essai randomisé et contrôlé

Rubrique ouverte à tous en lecture seule.
POUR ACCEDER AUX NOMBREUX AUTRES FORUMS IL EST NECESSAIRE DE S'INSCRIRE (fonction M'enregistrer en haut à droite de l'écran).
Répondre
Avatar du membre

Auteur du sujet
Pboulanger
Administrateur
Administrateur
Messages : 4897
Enregistré le : 02 févr. 2010 18:41
Localisation : La Chapelle en Serval F-60520
    Windows 8.1 Firefox
Genre :
Zodiaque : Lion
Âge : 61
Contact :
France

Efficacité de la prednisone (cortisone) pour le traitement de la myasthénie oculaire : Un essai randomisé et contrôlé

Message par Pboulanger » 28 janv. 2016 14:58

:hi:

Lu sur Willey On Line Library http://onlinelibrary.wiley.com/doi/10.1 ... avedsearch
Traduction disponible directement en cliquant en bas à droite de ce message sur notre forum
Image
Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): A randomized, controlled trial
Michael Benatar MD, PhD*, Michael P. Mcdermott PhD, Donald B. Sanders MD, Gil I. Wolfe MD, Richard J. Barohn MD, Richard J. Nowak MD, Michael Hehir MD, Vern Juel MD, Hans Katzberg MD, Rabi Tawil MD andMuscle Study Group (MSG)

Article first published online: 27 JAN 2016 DOI: 10.1002/mus.24769


ABSTRACT
  • Introduction:
    In this study we evaluated the safety, tolerability, and efficacy of prednisone in patients with ocular myasthenia gravis (OMG) concurrently treated with pyridostigmine.
  • Methods:
    This investigation was a randomized, double-blind, placebo-controlled trial. Participants whose symptoms failed to remit on pyridostigmine were randomized to receive placebo or prednisone, initiated at 10 mg every other day, and titrated to a maximum of 40 mg/day over 16 weeks. The primary outcome measure was treatment failure.
  • Results:
    Fewer subjects were randomized than the 88 planned. Of the 11 randomized, 9 completed 16 weeks of double-blind therapy. Treatment failure incidence was 100% (95% CI 48%–100%) in the placebo group (n = 5) vs. 17% (95% CI 0%–64%) in the prednisone group, P = 0.02 (n = 6). Median time to sustained minimal manifestation status (MMS) was 14 weeks, requiring an average prednisone dose of 15 mg/day. Adverse events were infrequent and generally mild in both groups.
  • Conclusions:
    A strategy of low-dose prednisone with gradual escalation appears to be safe, well-tolerated, and effective in treating OMG.
Muscle Nerve, 2015
Amicalement,
Image

Répondre

Retourner vers « Informations »